CI 959

Drug Profile

CI 959

Latest Information Update: 28 Jun 1999

Price : $50

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Antihistamines; Small molecules
  • Mechanism of Action Histamine release inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Allergic rhinitis; Asthma; Cancer; Crohn's disease; Ischaemic heart disorders; Peptic ulcer; Ulcerative colitis

Most Recent Events

  • 28 Jun 1999 Discontinued-I for Allergic rhinitis in USA (Unknown route)
  • 28 Jun 1999 Discontinued-I for Ischaemic heart disorders in USA (Unknown route)
  • 28 Jun 1999 Discontinued-II for Asthma in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top